This supports the combined use of lenalidomide and rituximab in a clinical setting. Finally, superresolution Stimulated Emission Depletion (STED) microscopy revealed that lenalidomide increased the periodicity of cortical actin at immune synapses, resulting in an increase in the area of the actin mesh predicted to be penetrable to vesicles containing IFN-γ. This establishes that nanometre-scale rearrangements in cortical actin, a recently discovered step in immune synapse assembly, are a potential new target for therapeutic compounds.
Introduction
NK cells contribute to defence against cancer by lysis of diseased or stressed cells and secretion of inflammatory cytokines including IFN-γ 1, 2 . NK cell responses are triggered through germline encoded activating receptors, including Natural Killer Group 2 member D (NKG2D), which recognises stress-inducible ligands such as MHC Class I chain-related protein A (MICA), and the Fc receptor CD16, which mediates antibody-dependent cellular cytotoxicity (ADCC) [3] [4] [5] [6] [7] [8] . Super-resolution microscopy revealed that activating receptor ligation triggers remodelling of cortical actin in specific domains within the NK cell immune synapse where lytic granules and vesicles containing IFN-γ accumulate [9] [10] [11] [12] [13] .
Multiple myeloma (MM) is a haematological malignancy characterised by a clonal proliferation of plasma cells in bone marrow and is associated with progressive dysregulation of the immune system 14 . NK cells may initially contribute to the control of malignant cells [15] [16] [17] and evidence suggests that NKG2D is involved in NK cell recognition of bone marrow-derived MM cells 18 . However, NK cell surveillance and cytotoxicity against MM decreases as the disease progresses [19] [20] [21] [22] [23] . There is some evidence that lenalidomide, used for the treatment of MM, can increase NK cell-mediated lysis 24 . However, studies also report that lenalidomide does not directly affect NK cell effector functions 25, 26 but rather helps via CD4+ T cell activation 26 .
Here, we establish that lenalidomide augments NK cell responses directly on both a population level and a single cell level. Crucially, lenalidomide lowered the threshold for NK cell activation through both CD16 and NKG2D, including via rituximab, indicating that NK cells could respond to lower densities of activating ligand. Also, super-resolution STED microscopy revealed that lenalidomide works to augment actin remodelling at the NK cell immune synapse.
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Methods
Cells
Primary human NK cells were obtained from healthy donor peripheral blood by negative magnetic selection and cultured as previously described 27 . NK cells were then used 6 days later, unless otherwise stated. Daudi and Raji were cultured in RPMI 1640 (Sigma-Aldrich), 10% fetal calf serum (FCS; Gibco), 2 mM L-glutamine (Gibco) and 1 mM penicillin and streptomycin (Sigma-Aldrich). NK cells were treated with lenalidomide (Celgene Corporation; 30 mM stock in DMSO) at a final concentration of 0.001 µM -10 µM (as indicated) in culture medium. 150 U/ml hrIL-2 was added alongside lenalidomide or vehicle control (DMSO), unless otherwise indicated. Where indicated, cells were also treated with brefeldin A (5 µg/ml; Sigma-Aldrich).
Cytotoxicity Assay
NK cell cytotoxicity was assessed against Daudi in a standard 5 hour 35 S-methionine release assay in triplicate. pNK cells were added to the target cells at an E:T ratio of 10:1 (5 x 10 4 pNK cells per well).
After 5 hours, 35 S activity in the supernatant was quantified (MicroBeta, Perkin Elmer) and results expressed as percent lysis: (experimental release -spontaneous release)/(maximal releasespontaneous release).
ELISA
NK cells were treated with 0.1-10 µM lenalidomide or DMSO, plus 150 U/ml IL-2 and were plated on antibody-or ligand-coated 96 well plates (100,000 pNK cells per well) and incubated for 24 hours at 37°C (5% CO 2 ). Antibodies against CD16 (Clone 3G8 BD Biosciences, 1 µg/ml), NKG2D (Clone 149810, R&D systems, 3 µg/ml), 2B4 (Clone 2-69, BD Biosciences, 3 µg/ml) and murine IgG1 isotype control (BD Biosciences) were used. Recombinant proteins used were MICA-Fc (R&D systems; 2 µg/ml unless otherwise stated), ICAM-1 (R&D systems, 2.5 µg/ml) and human IgG (Sigma-Aldrich, 1-500 µg/ml). 
Quantitative RT-PCR
Cells were treated with 1 µM lenalidomide or DMSO plus 150 U/ml IL-2 and were plated on glass slides coated with 0.01% poly-L-lysine and then mAb or recombinant proteins in PBS for 4 hours at 37°C. Antibodies used were anti-CD16 mAb (Clone 3G8 BD Biosciences; 3 µg/ml) and murine IgG1 isotype control (BD Biosciences; 3 µg/ml). Recombinant proteins used were MICA-Fc (R&D systems; 2 µg/ml) and ICAM-1 (R&D systems; 2.5 µg/ml). Cells were then lysed and RNA extracted using an RNeasy kit (Qiagen). RNA was reverse transcribed, and subjected to qPCR (Applied biosystems, CA, USA) using Sybr Green detection for IFN-γ using the following primer pair: Forward primer -5'-AAAAATAATGCAGAGCCAAATTG -3'; Reverse primer -5'-TAGCTGCTGGCGACAGTTCA -3'. Data analysed by δδCT method (Livak and Schmittgen 402-08); gene expression was normalised to the housekeeping gene GAPDH , which was detected using the following primer pair: Forward primer -5'-GAAGGTGAAGGTCGGAGT -3' ; Reverse primer -5'-CATGGGTGGAATCATATTGGAA -3' .
Preparation of coated slides
Eight-well borosilicate coverglass chambers (Lab-Tek, Nunc) were coated with 0.01% poly-L-lysine and then coated with mAb or recombinant proteins in PBS. Antibodies against the following proteins 6 were used: CD16 (Clone 3G8, BD Biosciences; 3 µg/ml), murine IgG1 isotype control (BD Biosciences), NKG2D (Clone 149810, R&D systems; 3 µg/ml). Rituximab (Invivogen) was also used (10 µg/ml). Recombinant proteins used were MICA-Fc (R&D systems; 2 µg/ml) and ICAM-1 (R&D systems; 2.5 µg/ml).
Microscopy
Cells were incubated as indicated and fixed in 4% paraformaldehyde and permeabilised with 0.1%
Triton-X-100. For NKG2D and LFA-1 co-stimulation, cells were incubated for 90 min before fixation, as identified as the optimal for IFN-γ production 13 . 
Image analysis
For the single cell IFN-γ analysis, confocal images were imported into Imaris software (Bitplane).
Individual cells were segmented based on cell body staining (Atto-590 phalloidin) and nucleus staining (NucBlue). IFN-γ vesicles were identified based on Alexa488-IFN-γ mAb staining within each cell. STED images were deconvolved (Huygens; Scientific Volume Imaging), exported in tagged image file format and analysed using MATLAB (Mathworks) as previously described 9 .
Statistical analyses
Mean values and SEM are shown. Data was analysed by one-way ANOVA and Tukey's post-test (Prism version 6; GraphPad). For threshold analysis, IFN-γ production was normalised to the 7 maximum value seen with each receptor and EC 50 was determined by nonlinear regression (Prism version 6; GraphPad).
Results
Lenalidomide directly affects NK cell IFN-γ secretion after activation through different receptors
To test whether lenalidomide affects NK cells directly, human pNK cells were isolated and co-incubated with Daudi cells (a B cell lymphoma line susceptible to NK cell cytotoxicity) in the presence of increasing concentrations of lenalidomide (0.001-10 µM). Lysis of Daudi target cells was significantly enhanced with 0.1-10 µM lenalidomide in the presence of IL-2 (Fig. 1A) . The addition of 10 µM lenalidomide, increased the specific lysis of target cells from 13 ± 2% to 30 ± 1% (Fig. 1A) . 
Lenalidomide increases the proportion of cells secreting IFN-γ as well as the amount of cytokine produced per cell
The enhancement in IFN-γ secretion with lenalidomide treatment could involve an increase in the number of NK cells secreting IFN-γ and/or an increase IFN-γ production from individual cells.
To test this, pNK cells were incubated on glass slides coated with anti-CD16 mAb in the presence of 0.1-10 μM lenalidomide. Cells were fixed and then imaged by confocal microscopy ( Fig. 2A) . In the absence of lenalidomide, expression of IFN-γ protein could be detected within 30 min in a small proportion of primary NK cells (2.5 ± 1.5%) and peaked after 120 min stimulation, when 22 ± 1% pNK cells expressed IFN-γ (Fig. 2B) . The percentage of pNK cells expressing IFN-γ decreased by 240 min suggesting that the majority of IFN-γ had been secreted by this time (Fig. 2B , white bars). The effect of 1 µM lenalidomide also peaked 120 min after stimulation, almost doubling the proportion of NK cells expressing IFN-γ from 22 ± 1% to 41 ± 3% (Fig. 2B, striped bars) . In a separate experiment, to control for lenalidomide treatment time, cells were treated at the start of the experiment and added to anti-CD16 mAb coated surfaces in reverse order for the time course. This meant, for example, that cells undergoing 30 min stimulation had 210 min incubation with lenalidomide prior to plating (Fig. 2C ). This confirmed that the effect of lenalidomide on pNK cell IFN-γ production occurs after 90 min of stimulation. 
Lenalidomide lowers the threshold for NK cell activation
Functionally, a threshold concentration of MICA is required for NKG2D-mediated cytolysis of target cells 28 . To test whether lenalidomide influenced the threshold density of MICA proteins needed to activate pNK cells, cells were incubated on surfaces coated with increasing concentrations of MICA (0.1-10 µg/ml) and ICAM-1 (2.5 µg/ml). We then determined the effective concentration of activating receptor that elicited half-maximal responses (EC 50 ) (Fig. 3A) . Lenalidomide treatment resulted in 38% decrease in the MICA EC 50 , from 2.1 µg/ml without lenalidomide to 1.3 µg/ml with lenalidomide ( Fig. 3A) . A threshold level of CD16 ligation needed to activate NK cells has also been 11 observed 29 . Lenalidomide caused a 66% decrease in the EC 50 of immobilised human IgG (hIgG; the cognate ligand for CD16), from 62 µg/ml without lenalidomide to 21 µg/ml with lenalidomide ( Fig.   3B ). Together, these data establish that lenalidomide lowers the threshold for NK cell activation through different activating receptors.
To observe the effect of activating ligand concentration on IFN-γ production at the single cell level, pNK cells were imaged by confocal microscopy at 1-5 µg/ml MICA (Fig. 3C) . Lenalidomide treatment significantly increased the proportion of cells secreting IFN-γ when stimulated by 2.5 µg/ml MICA (33 ± 1.7% without lenalidomide; 55 ± 2.6% with lenalidomide), but not for 1 µg/ml MICA ( Fig. 3D ). At 5 µg/ml MICA both conditions showed a similar proportion of cells with IFN-γ protein expression (Fig. 3D ). This shows that there is a threshold concentration of MICA above which lenalidomide treatment increases the proportion of cells expressing IFN-γ. Interestingly, lenalidomide treatment resulted in a significant increase in the amount of IFN-γ expression per cell in all concentrations of MICA tested (Fig. 3E ). This establishes that lenalidomide has two effects on cells: at any level of NK cell stimulation, lenalidomide increases the amount of IFN-γ produced per cell and, in addition, lenalidomide lowers the threshold for activation so that a greater proportion of NK cells are involved in the response.
Lenalidomide alters the periodicity of the actin mesh at the NK cell ADCC synapse
A nanoscale re-organisation of synaptic actin has been observed prior to IFN-γ secretion 13 .
To test the effect of lenalidomide on actin remodelling, pNK cells were treated with 1 µM lenalidomide and stimulated on surfaces coated with anti-CD16 or an isotype-matched control mAb for 120 min, and F-actin imaged by STED microscopy (Fig.4A) . Areas between individual actin filaments within the central region of the synapse, "holes" 9 , were calculated and false colour heat maps were created to display the variation (Fig. 4A) . The "penetrable area" that would allow passage 12 of vesicles of 200-500 nm diameter -the size of the majority of vesicles containing IFN-γ (Fig. 4B) - was also calculated and displayed as a false colour heat map (Fig. 4A ).
For control-treated cells, the mean area of holes between actin filaments was 0.055 ± 0.004
, and did not change significantly in the presence of lenalidomide (Fig. 4C) . The penetrable area also did not significantly change with lenalidomide (Fig. 4D) , consistent with the results from Fig. 1 , where lenalidomide only has an effect when accompanied by activating receptor ligation. When cells were stimulated by anti-CD16 mAb, the mean hole area significantly increased (Fig. 4C ) and lenalidomide caused a small, but not significant, further increase, from 0.74 ± 0.004 µm 2 to 0.89 ± 0.005 µm 2 ( Fig. 4C) . However, lenalidomide increased the penetrable area of the synapse nearly two-fold for a wide range of vesicle sizes (Fig. 4D ). This indicates that, after lenalidomide treatment, a higher proportion of the actin mesh has opened up to become permissive to IFN-γ vesicles.
Lenalidomide increased the penetrable area within the actin mesh, irrespective of whether or not the NK cells stained for IFN-γ (in the presence of brefeldin A to block IFN-γ release; Fig. 4E ), and, unlike the enhancement of IFN-γ production after lenalidomide treatment, the increase in cortical actin remodelling by lenalidomide was independent of IL-2 (Fig. 4F) . Overall, these data establish that lenalidomide influences the nanoscale organisation of cortical actin at the NK cell synapse.
For pNK cells stimulated on anti-CD16 mAb for only 6 minutes, the proportion of the synapse predicted to be penetrable by lytic granules (of at least 250 nm diameter; as defined previously 9 ) was 1.5 ± 0.15% in DMSO-treated cells and increased to 1.9 ± 0.2% in lenalidomide treated cells ( Fig.   5A and 5B). The penetrable area of the cortical actin mesh increased significantly after lenalidomide treatment in cells that were activated (determined by a dense ring of F-actin at the synapse periphery; Fig. 5C ). Thus, lenalidomide treatment also augments cortical actin remodelling at an early time point, relevant for lytic granule secretion, although to a lesser extent than observed later, at the time point relevant for cytokine secretion.
Lenalidomide alters the periodicity of the actin mesh after NKG2D and LFA-1 co-ligation
NKG2D is a major NK cell receptor responsible for the recognition of MM cells. We therefore tested the effect of lenalidomide treatment following NKG2D ligation (Fig. 6A) . When pNK cells were in contact with slides coated with ICAM-1 alone, the mean hole area both with and without lenalidomide treatment was <0.053 µm 2 ( Fig. 6B ) and the percentage area of the synapse predicted to be penetrable by IFN-γ vesicles was <0.7% (Fig. 6C) . Ligation of NKG2D resulted in an opening of the cortical actin mesh (Fig. 6B and C) but crucially, lenalidomide enhanced actin remodelling only when NKG2D and LFA-1 were co-ligated (Fig. 6C) . NKG2D engagement does not lead to NK cell effector functions without LFA-1 co-ligation 7 and hence this is further evidence that lenalidomide augments rather than triggers cellular activation.
Lenalidomide augments NK cell activation after rituximab ligation
Lenalidomide in combination with anti-CD20 mAb rituximab is currently in clinical trials for some lymphomas 30, 31 . To test whether lenalidomide influenced NK cell activation by rituximab, lenalidomide-treated pNK cells were incubated on surfaces coated with increasing concentrations of rituximab (0.0001-100 µg/ml). A distinct threshold for NK cell activation was observed and there was a 74% decrease in the EC 50 in lenalidomide-treated cells (1.7 µg/ml to 0.4 µg/ml; Fig. 7A ). This indicates that lenalidomide lowers the minimum concentration of rituximab required to activate NK cells.
We then used microscopy to visualise the effect of lenalidomide on rituximab activation at the single cell level. Rituximab-activated pNK cells produced IFN-γ at an earlier time point, 60 mins, than seen when pNK cells were activated with an anti-CD16 mAb ( Fig. 7B and 2B respectively) . Thus, pNK cells were incubated on glass slides coated with 10 µg/ml rituximab for 60 mins and imaged (Fig. 7C) . Lenalidomide treatment led to a significant increase in the percent area of the synapse 14 predicted to be penetrable to a vesicle of 200-350 nm diameter (Fig. 7D ). This effect was also observed at 120 min (Fig. 7E) . Thus, lenalidomide increases the sensitivity of NK cells to rituximab, supporting the combined use of lenalidomide and rituximab in the treatment of B cell malignancies.
Discussion
Lenalidomide has significantly improved overall survival in myeloma patients, but recent studies have focused on the mechanism associated with T cell activation [32] [33] [34] [35] . Here, we establish that lenalidomide augments NK cell effector functions triggered through different activating receptors.
This implies that lenalidomide acts downstream of receptor proximal signalling, as the signal pathways for CD16-and NKG2D-mediated activation are distinct and converge later. We show that Recently, nanoscale remodelling of actin at the NK cell immune synapse has been recognised as important for directed secretion 9, 10, 13 . Previously actin remodelling was considered a binary, 'allor-nothing' response but here we found that lenalidomide treatment augments the extent of actin remodelling at the NK cell synapse. Specifically, lenalidomide treatment resulted in a 2-fold increase in the area of the synapse predicted to be penetrable by a vesicle of 200-500 nm diameter. It is possible that the lenalidomide-enhanced actin remodelling in NK cells could be linked to the mechanism by which this drug restores synapse assembly in T cells from Chronic Lymphocytic Leukaemia patients [36] [37] [38] . Importantly, our data also provides the first evidence that synaptic actin remodelling is druggable, indicating that new compounds could be screened for an effect on cortical actin to augment NK cell responses.
Finally, we have shown that lenalidomide also affects NK cell activation after ligation of CD16 with rituximab, which is currently in clinical trials in combination with lenalidomide 30, 31 . Here, we 16 establish that lenalidomide lowers the threshold for NK cell activation through rituximab, consistent with increased ADCC. 24, 39, 40 Overall, our results demonstrate a direct and significant effect of 
